Abstract：
UNASSIGNED: Tuberculosis (TB) is a leading infectious disease cause of mortality worldwide, especially for people living with human immunodeficiency virus (PLWH). Treating TB in PLWH can be challenging due to numerous drug interactions.
UNASSIGNED: This review discusses drug interactions between antitubercular and antiretroviral drugs. Due to its clinical importance, initiation of antiretroviral therapy in patients requiring TB treatment is discussed. Special focus is placed on the rifamycin class, as it accounts for the majority of interactions. Clinically relevant guidance is provided on how to manage these interactions. An additional section on utilizing therapeutic drug monitoring (TDM) to optimize drug exposure and minimize toxicities is included.
UNASSIGNED: Antitubercular and antiretroviral coadministration can be successfully managed. TDM can be used to optimize drug exposure and minimize toxicity risk. As new TB and HIV drugs are discovered, additional research will be needed to assess for clinically relevant drug interactions.
UNASSIGNED: This review discusses drug interactions between antitubercular and antiretroviral drugs. Due to its clinical importance, initiation of antiretroviral therapy in patients requiring TB treatment is discussed. Special focus is placed on the rifamycin class, as it accounts for the majority of interactions. Clinically relevant guidance is provided on how to manage these interactions. An additional section on utilizing therapeutic drug monitoring (TDM) to optimize drug exposure and minimize toxicities is included.
UNASSIGNED: Antitubercular and antiretroviral coadministration can be successfully managed. TDM can be used to optimize drug exposure and minimize toxicity risk. As new TB and HIV drugs are discovered, additional research will be needed to assess for clinically relevant drug interactions.
摘要：
■结核病（TB）是全球主要的传染病死亡原因，特别是对于患有人类免疫缺陷病毒（PLWH）的人。由于许多药物相互作用，在PLWH中治疗结核病可能具有挑战性。
■这篇综述讨论了抗结核和抗逆转录病毒药物之间的药物相互作用。由于其临床重要性，讨论了在需要结核病治疗的患者中开始抗逆转录病毒治疗。特别关注利福霉素类,因为它占了大多数互动。提供了关于如何管理这些相互作用的临床相关指导。还包括关于利用治疗药物监测（TDM）来优化药物暴露并最大程度地减少毒性的其他部分。
■抗结核和抗逆转录病毒联合给药可以成功管理。TDM可用于优化药物暴露并最小化毒性风险。随着结核病和艾滋病毒药物的发现，还需要进行更多的研究来评估临床相关的药物相互作用.
■这篇综述讨论了抗结核和抗逆转录病毒药物之间的药物相互作用。由于其临床重要性，讨论了在需要结核病治疗的患者中开始抗逆转录病毒治疗。特别关注利福霉素类,因为它占了大多数互动。提供了关于如何管理这些相互作用的临床相关指导。还包括关于利用治疗药物监测（TDM）来优化药物暴露并最大程度地减少毒性的其他部分。
■抗结核和抗逆转录病毒联合给药可以成功管理。TDM可用于优化药物暴露并最小化毒性风险。随着结核病和艾滋病毒药物的发现，还需要进行更多的研究来评估临床相关的药物相互作用.
